Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Tomisaku Kawasaki, Pediatrician Who Discovered Disease That Bears His Name, Dies at 95

Renée Bacher  |  Issue: August 2020  |  June 18, 2020

Dr. Kawasaki

Dr. Kawasaki

Japanese pediatrician Tomisaku Kawasaki, MD, who identified an inflammatory syndrome that affects children, died on June 5 in Tokyo. He was 95.

Tenacity & Attention to Detail
Born Feb. 7, 1925, in Tokyo, Dr. Kawasaki graduated from medical school at what is now Chiba University in Chiba, Japan, in 1948 and worked as staff pediatrician at the Red Cross Hospital in suburban Tokyo. It was there in 1961 that he saw his first patient with the disease that would eventually bear his name. Kawasaki disease has been in the news recently because some children testing positive for COVID-19 have exhibited comparable symptoms, including rash and extremely bloodshot eyes. “The connection between [the conditions] is a wide open question right now,” says pediatrician Jane Burns, MD, director of the Kawasaki Disease Research Center at the University of California, San Diego.

Dr. Kawasaki with Dr. Burns

Dr. Kawasaki with Dr. Burns

Dr. Kawasaki’s patient was a 4-year-old patient with unusual symptoms he could not diagnose. “The boy presented with a fever, congestion of the mucous membranes, cervical lymphadenopathy and desquamation,” says Philip Seo, MD, MHS, associate professor of medicine at the Johns Hopkins University School of Medicine, Baltimore, director of both the Johns Hopkins Vasculitis Center and the Johns Hopkins Rheumatology Fellowship Program, and physician editor of The Rheumatologist. “The patient eventually improved on his own and was discharged with the honest label of ‘diagnosis unknown.’”

Dr. Kawasaki subsequently had seven more patients with these unusual symptoms, which he documented in great detail and presented as a case series at a meeting of the Japanese Pediatric Association. When he submitted the series for publication, it was rejected; the reviewers suggested he had observed an atypical form of Stevens-Johnson syndrome.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“There was almost an idea that because he was outside of the establishment, he could not possibly have described a new disease,” says Dr. Burns, who first met Dr. Kawasaki when she was a young infectious disease fellow and over the years came to consider him a dear friend.

During the next six years Dr. Kawasaki documented 50 similar cases of children with symptoms that included high fevers, extremely red eyes and lips, and a swollen red tongue, as well as swollen, peeling hands and feet. This case series was published.

“Maybe because he was unfettered by too much training, he could just see clearly what was in front of him,” says Dr. Burns. “Can you imagine today a rheumatologist waiting to report a new condition and gathering 50 patients over a period of years?”

Page: 1 2 3 4 | Single Page
Share: 

Filed under:Professional TopicsProfiles Tagged with:KawasakiKawasaki diseaseTomisaku Kawasaki

Related Articles

    Thinking Big, Thinking Small

    June 17, 2019

    I would like to tell you a story. Two, actually. I am just returning from the 19th International Vasculitis and ANCA Workshop, which is always a fascinating meeting. In its inception, it was a workshop, in the true sense of the word. Now, we discuss anti-neutrophil cytoplasmic antibody (ANCA) testing as casually as we discuss…

    Exploring Kawasaki Disease

    April 2, 2014

    New epidemiologic data, clinical studies have shed light on diagnosis, treatments, patient outcomes for this childhood disease, but etiology is still unknown

    MIA Studio / shutterstock.com

    Kawasaki Guideline Urges Treatment Intensification for Some Patients

    December 16, 2021

    A soon-to-be published guideline from the ACR and the Vasculitis Foundation on Kawasaki disease underscores the importance of early diagnosis and intensified treatment for people with this serious condition.1 Intravenous immunoglobulin (IVIG) remains the treatment mainstay, and prompt, aggressive treatment may be able to reduce the risk of serious complications in some patients. The guideline…

    2013 ACR/ARHP Annual Meeting: Diagnostic,Treatment Approaches Evolve for Kawasaki Disease

    February 1, 2014

    New data examine infliximab as a treatment option, and updated diagnostic criteria aids physicians in recognizing KD and detecting cardiac involvement in patients

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences